XOCOVA gives pediatricians a new oral option to help prevent COVID-19 after exposure in adolescents aged 12 years and older.

At AAP 2026, Rana Hamdy, MD, discussed when to test children for group A strep, antibiotic selection, and strategies to improve prescribing.

New ecopipam analyses show tic reduction within 8 weeks and sustained to 18 months in Tourette syndrome as the FDA weighs approval.

Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.

A recap of the top clinical trial and pipeline data readouts affecting pediatric care during September 2026.

Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.

A recap of the top FDA approvals/regulatory decisions/pipeline updates affecting pediatric care during September 2026.

Joseph Rossano, MD, discusses how FDA approval of mavacamten introduces a disease-targeted treatment option for adults and pediatric patients weighing 30 kg (66 lbs) or more with symptomatic oHCM.